1529 NOVEL NON-PEPTIDE PHARMACOLOGIC THERAPY FOR NOCTURIA IN MEN

You have accessJournal of UrologyUrodynamics/Incontinence/Female Urology: Non-Neurogenic Voiding Dysfunction I1 Apr 20101529 NOVEL NON-PEPTIDE PHARMACOLOGIC THERAPY FOR NOCTURIA IN MEN Mariam Imnadze, Jeffrey Weiss, Christopher Yea, Brian Marks, Hilary McElwaine-Johnn, and Mahendra Nathadwarawala Mariam ImnadzeMariam Imnadze Brooklyn, NY More articles by this author , Jeffrey WeissJeffrey Weiss Brooklyn, NY More articles by this author , Christopher YeaChristopher Yea Southampton, United Kingdom More articles by this author , Brian MarksBrian Marks Brooklyn, NY More articles by this author , Hilary McElwaine-JohnnHilary McElwaine-Johnn Southampton, United Kingdom More articles by this author , and Mahendra NathadwarawalaMahendra Nathadwarawala Plymouth, United Kingdom More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1280AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES This study reports the effects of a novel non-peptide drug, 1- [2 - methyl - 4 -(2,3,4,5 tetrahydro-1 -benzazepin-1 -ylcarbonyl) benzyl- carbamoyl] -L-prolineN,N-dimethylamide (VA106483), a selective vasopressin V2-receptor agonist, on urinary volume and osmolality in elderly males with nocturia. METHODS Twenty-seven subjects, mean age 69.4 years were randomized in this IEC approved, double-blinded, placebo controlled study conducted at a single center and subdivided into 3 cohorts, each consisting of 9 subjects. In each cohort, 3 subjects received VA106483 (2mg, 4mg or 8mg) and 6 subjects received placebo on the first night. On nights 2 through 8, subjects crossed over to receive the alternative treatment - 6 received VA106483 and 3 received placebo for 7 consecutive nights of repeated dosing. All subjects underwent pre-treatment water loading 2 hours before dosing at 0h on nights 1, 2 and 8. At designated time intervals, determination was made of serum electrolytes, urine osmolality and urine volume RESULTS The population mean age was 69.4 years (SD 3.5) with a mean BMI of 26.1 kg/m2(SD 2.8) At all doses, mean urine osmolality increased after drug administration in a dose-dependent fashion as compared with placebo (see figure). At all doses, diuresis decreased after drug administration compared to placebo. Response to the drug did not dissipate during continued dosing, and the change in urine osmolality and diuresis on night 8 did not statistically differ from that on night 2 for all doses. CONCLUSIONS VA106483 increased urine osmolality and reduced diuresis in all elderly men with a history of nocturia in the study, with an increasing duration of anti-diuresis corresponding to increased doses from 2 to 8 mg. The effect and duration of anti-diuresis remained constant after repeated doses. Clinical application of the drug in doses up to 4 mg predictably produce antidiuretic response to reduce the number of nocturnal voids. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e590 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.Metrics Author Information Mariam Imnadze Brooklyn, NY More articles by this author Jeffrey Weiss Brooklyn, NY More articles by this author Christopher Yea Southampton, United Kingdom More articles by this author Brian Marks Brooklyn, NY More articles by this author Hilary McElwaine-Johnn Southampton, United Kingdom More articles by this author Mahendra Nathadwarawala Plymouth, United Kingdom More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...